Home/Investors/Public Shareholders

Public Shareholders

Biotech Investor · 69 portfolio companies

Portfolio
69
Combined Value
$11394.7B
Focus Areas
73
Top Stage
commercial

Portfolio Companies

CompanyValuation
Yuhan$6474.6B
Cipla$1088.1B
Sumitomo Pharma$640.8B
Biocon$616.0B
Shinpoong Pharm$590.0B
KOBAYASHI Pharmaceutical$439.0B
Gland Pharma$313.8B
Piramal Pharma$238.3B
Hansoh Pharma$219.7B
Natco Pharma$210.4B
Kissei Pharmaceutical$181.1B
GSK plc$100.7B
FDC India$61.9B
Huadong Medicine (HD Medicine)$58.3B
Edwards Lifesciences$46.8B
Guangzhou Baiyunshan Pharmaceutical Holdings$37.0B
PharmaMar$22.1B
Joincare Pharmaceutical Group Industry Co.$19.7B
Smith and Nephew$12.8B
Recordati$10.2B
Grifols$5.5B
Siegfried Holding$3.6B
Ligand Pharmaceuticals$2.5B
Vetoquinol$860.2M
Tilray$662.0M
Moberg Pharma$79.6M
InterCure$47.3M
NGM Biopharmaceuticals
Carmat
Vapotherm
Medicilon
Mabwell Biotech
Luye Pharma
Henlius Biopharmaceuticals
Green Valley Pharmaceuticals
Eddingpharm
SNIBE Diagnostics
Syneron Bio
Zydus Cadila
Boan Biotech
Aosaikang Pharmaceutical
Shandong Luoxin Pharmaceutical
Chia Tai TianQing Pharmaceutical Group
Qilu Pharmaceutical
Kexing Biopharm
Bloomage Biotech
Viva Biotech
Sino Biopharmaceutical
galderma
Essex Bio
China Medical Systems
Zylox-Tonbridge
Sinopep
Huadong Medicine
Medipost
Daan Gene
Bio-Thera Solutions
Baird Medical
Taisho Pharmaceutical
Porton Pharma Solutions
Respirent Pharmaceuticals Co
Maccura Biotechnology
HitGen
Chengdu Kanghong Pharmaceutical Group
Sansure Biotech
Dirui Industrial
Yabao Pharmaceutical
Acotec
Schrödinger, Inc.